Bulltick Wealth Management LLC Acquires New Stake in Quanterix Co. (NASDAQ:QTRX)

Bulltick Wealth Management LLC bought a new position in shares of Quanterix Co. (NASDAQ:QTRX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 59,500 shares of the company’s stock, valued at approximately $786,000. Bulltick Wealth Management LLC owned approximately 0.16% of Quanterix as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its position in shares of Quanterix by 3.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,916 shares of the company’s stock worth $941,000 after purchasing an additional 1,186 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Quanterix by 11.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 14,261 shares of the company’s stock worth $188,000 after buying an additional 1,417 shares during the last quarter. Olympiad Research LP raised its position in shares of Quanterix by 20.9% during the 4th quarter. Olympiad Research LP now owns 16,182 shares of the company’s stock valued at $442,000 after buying an additional 2,799 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Quanterix by 34.7% during the 2nd quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock worth $164,000 after acquiring an additional 3,279 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its position in Quanterix by 42.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 14,341 shares of the company’s stock worth $338,000 after acquiring an additional 4,250 shares in the last quarter. 86.48% of the stock is currently owned by institutional investors.

Insider Activity at Quanterix

In other news, Director David R. Walt acquired 47,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were purchased at an average price of $13.29 per share, for a total transaction of $624,630.00. Following the completion of the transaction, the director now owns 1,487,342 shares of the company’s stock, valued at $19,766,775.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on QTRX shares. The Goldman Sachs Group lowered their price target on Quanterix from $35.00 to $24.00 and set a “buy” rating on the stock in a research report on Tuesday, July 9th. TD Cowen decreased their price objective on Quanterix from $17.00 to $15.00 and set a “hold” rating on the stock in a report on Friday, August 9th. Finally, Scotiabank cut their target price on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating for the company in a research note on Monday, August 12th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.80.

Quanterix Trading Down 6.1 %

QTRX opened at $14.54 on Friday. Quanterix Co. has a 12 month low of $10.50 and a 12 month high of $29.70. The business’s 50-day moving average price is $13.43 and its 200-day moving average price is $16.45. The company has a market cap of $558.05 million, a P/E ratio of -15.15 and a beta of 1.36.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The company had revenue of $34.38 million during the quarter, compared to analysts’ expectations of $34.19 million. Quanterix had a negative return on equity of 11.52% and a negative net margin of 30.71%. During the same period last year, the firm earned ($0.16) earnings per share. Equities research analysts forecast that Quanterix Co. will post -0.88 earnings per share for the current fiscal year.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.